Partners Pfizer, BioNTech Seek Emergency Vaccine Authorization From FDA
Pharmaceutical company Pfizer and its German partner, BioNTech, said Friday they have filed for emergency authorization from the U.S. Food and Drug Administration (FDA) to use their COVID-19 vaccine, saying they are poised to begin distribution within hours after authorization. The application comes after the companies said testing shows the vaccine has an effectiveness rate of 95 percent, with no serious safety concerns observed to date. In a news release, the companies say in addition to their submission to the FDA, they are seeking authorization from authorities in Australia, Canada, Europe, Japan and the U.K., and plan to submit applications immediately to other regulatory agencies around the world. FILE - A worker passes a line of freezers holding coronavirus disease vaccine candidate BNT162b2 at a Pfizer facility in Puurs, Belgium, in an undated…